Aphasia is a type of neurological disorder that is caused by factors which lead to damage to the language areas of the brain such as stroke, brain tumour, brain infection, gunshot wounds, and certain progressive neurological disorders such as Alzheimer’s disease and Parkinson’s disease. Aphasia is categorized into two types, non-fluent aphasia and fluent aphasia. Wernicke's aphasia is a type of fluent aphasia in which patients speak long sentences that have no meaning. Broca’s aphasia is a type of non-fluent aphasia in which patients speak short phrases that are produced with great effort. Axon Neuroscience SE is in the process of developing AADvac1 as a tau protein modulator for the treatment of aphasia. Some of the companies having the pipeline of aphasia include Axon Neuroscience SE, Neurotrope, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.